Pharmacokinetic Characteristics of Oral Hydroxysafflor Yellow A in Rats
HUANG Yu-ru1,2, ZHANG Jing-qing1, SHI Ming-xin3, WANG Ting-ting4, ZHAO Hua1*
1. Chongqing Research Center for Pharmaceutical Engineering, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; 2. Department of Pharmacy, The People′s Hospital of Dazu District, Chongqing 402360, China; 3. West China Second University Hospital, Sichuan University, Chengdu 610041, China; 4. Biochemistry and Molecular Biology Laboratory, Experimental Teaching and Management Center, Chongqing Medical University, Chongqing 400016, China
Abstract：OBJECTIVE To investigate the linear pharmacokinetics characteristics of hydroxysafflor yellow A (HSYA) in rats at different doses. METHODS Eighteen male SD rats were randomly divided into three groups. HSYA was administered intragastrically at doses of 30, 60 and 120 mg·kg-1 respectively. The blood samples were collected from rat fundus venous plexus at preset time points. The blood concentration of HSYA was determined by HPLC. The pharmacokinetic characteristics of HSYA in rats were analyzed by descriptive method and confidence interval method. RESULTS There were no dose dependence of non-atrioventricular and atrioventricular pharmacokinetic parameters clearance (CL), which were about 6 L·h-1·kg-1. The area under concentration-time curve (AUC) and peak concentration (ρmax) were correlated with the dosage of HSYA. CONCLUSION The pharmacokinetic parameters AUC of HSYA in the dose range of 30-120 mg·kg-1 have linear kinetic characteristics.
LU W D, ZHANG J Q. Biopharmaceutics and Pharmacokinetics(生物药剂学与药物动力学) [M]. Vol 1. Beijing: Science Press, 2017:204-220.
[2]
HUMMEL J, MCKENDRICK S, BRINDLEY C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat, 2009, 8(1):38-49.
[3]
TIAN Y, YANG Z F, YANG J, et al. Pharmacokinetics of hydroxysafflower yellow A in healthy volunteers.Chin Pharm J (中国药学杂志), 2009, 44(10):781-783.
[4]
YE X, KONG W, ZAFAR M I, et al. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and Meta-analysis of prospective studies. Cardiovasc Diabetol, 2019, 18(1):48.
[5]
SHI M X, GUO Q, HUANG Y R, et al. Pharmacokinetics of hydroxysafflor yellow A nanoemulsion water-in-oil. Chin Pharm J (中国药学杂志), 2018, 53(24):2108-2112.
[6]
ZHAO B, GU S, DU Y, et al. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A. Int J Pharm, 2018, 535(1-2):164-171.
[7]
QIAN X D, LV G Y, YUAN Y M, et al. Hydroxysafflower yellow A protects PC12 cells from injury induced by hypoxia, hypoglycemia and reperfusion and its effect on matrix metalloproteinase-9. Chin Pharm J (中国药学杂志),2013,48(9):691-695.
[8]
JIN P H. Medical Statistical Method (医用统计方法) [M]. Vol 2. Shanghai: Shanghai Medical University Press, 1993:128-131.
[9]
WANG J M, ZOU T, ZHANG Y Y, et al. Study on plasma protein binding rate of hydroxysafflor yellow A in safflor yellow powder injection. Chin Tradit Pat (中成药), 2011, 33(6):947-949.
[10]
LI X L, CUI G N, CUI Y. Literature analysis on adverse reactions of saffower yellower injection . J China Pharm(中国药房), 2015, 26(6):732-734.
[11]
ZHAO M,YANG J, WEI M J. Using confidence interval method to assess linear pharmacokinetics in dose escalation study. Chin J Clin Pharmacol(中国临床药理学杂志), 2015, 31(3):238-240.
[12]
NICOLAU G, FEIGHNER J P, STOUT R, et al. Comparison of systemic exposure to nemifitide following two METHODS of subcutaneous administration to healthy volunteers. Biopharm Drug Dispos, 2005, 26(9):379-385.
[13]
FORGUE S T, PATTERSON B E, BEDDING A W, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol, 2006, 61(3):280-288.
2020, Vol. 55 
